October 11, 2018. There are many unanswered questions about what dosages work and are safe for which patients under which conditions. We all know that is an epidemic of opioid use, so these questions must be answered before a decision is made about whether or not to approve oliceridine.
Read More »We’re Speaking Out on Health Issues
NCHR scientists and health policy experts provide written and oral statements on a wide range of topics.
Here are many of the ways we have been Speaking Out on Health Policy Issues for the last few years. Whether the topic is legislation intended to cure diseases, proposed bans on BPA or other chemicals that disrupt your hormones, the importance of including women, people of color, and patients over 65 in clinical trials, or many other topics, you’ll gain a better understanding of our evidence-based analyses by reading these letters, statements, and testimony.
Here are the ways we have been Speaking out on Medical Treatments and Products, such as prescription drugs and medical devices that the FDA is considering approving, or is considering taking off the market because of serious risks. Whether the topic is Chantix, Addyi, Yaz, Essure, or medical products you’ve never heard of, you can find out more about what is known and not known about the safety and effectiveness of a wide range of products by looking through this section of our website.
NCHR Comment on USPSTF Draft Recommendation Statement for Ocular Prophylaxis for Gonococcal Ophthalmia Neonatorum: Preventive Medication
In order for the U.S. to follow in the footsteps of Canada and other countries that have stopped universal prophylaxis, we recommend that USPSTF encourage physicians to have conversations or conduct counselling on STD’s and give pregnant mothers the option to opt out of neonatal prophylaxis.
Read More »NCHR Comment on Request for Information Regarding the 21st Century Cures Act
One important concern we at the National Center for Health Research have is the growing susceptibility of EHRs and health IT to hacking and other cybersecurity issues like ransomware.
Read More »NCHR Testimony on WEB Aneurysm Embolization System
September 27, 2018. There are important aspects of the clinical trial that make it difficult to determine if the WEB device is effective and safe for the indicated population. If the FDA does not demand better research, patients and their physicians may never know the answers to those questions.
Read More »NCHR Testimony on RJRT’s Camel Snus Advertising
September 14, 2018. The NCHR testifies at the FDA advisory board committee for tobacco products regarding advertisements that target the youth.
Read More »